Celland gene therapies are among the most expensive therapies within the healthcaresector1.Systematic reviews of economic evaluations of Chimeric antigen receptor T-cell(CAR-T) therapies for cancer treatment show that CAR-T therapies tend to bemore costly, but also more effective than comparative treatments1,2. AsCAR-T therapy use increases and large numbers of new advanced cell therapiesare developed, the CAR-T therapy management process needs to be optimized inorder to reduce the diagnosis to treatment time (turnaround process). Thisreduces therapy manufacturing time and associated costs, facilitating betteraccess for patients.
